Collecting Industry’s Thoughts on FDA FARS Report

FDA’s January 2021 release of its Focus Areas of Regulatory Science (FARS) report outlines topics that need continued targeted investment to advance regulatory science research that can facilitate the development of innovative products. The report also outlines the agency’s needs for data provision and methodology clarification to inform its regulatory decision-making process in the hopes that this will improve guidance for sponsors. Representatives from Bio-Process Systems Alliance and BioPhorum shared their thoughts on the report and provided feedback from an industry perspective.

Read this article in BioPharm International’s October 2021 Regulatory Sourcebook eBook.

About the author

Feliza Mirasol is the science editor for BioPharm International.

Article Details

BioPharm International
eBook: Regulatory Sourcebook, October 2021
October 2021
Pages: 4–5

Citation

When referring to this article, please cite it as F. Mirasol, “Collecting Industry’s Thoughts on FDA FARS Report," BioPharm International Regulatory Sourcebook eBook (October 2021).